396 related articles for article (PubMed ID: 30253922)
21. Circulating microRNA-based screening tool for breast cancer.
Frères P; Wenric S; Boukerroucha M; Fasquelle C; Thiry J; Bovy N; Struman I; Geurts P; Collignon J; Schroeder H; Kridelka F; Lifrange E; Jossa V; Bours V; Josse C; Jerusalem G
Oncotarget; 2016 Feb; 7(5):5416-28. PubMed ID: 26734993
[TBL] [Abstract][Full Text] [Related]
22. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.
Spizzo G; Obrist P; Ensinger C; Theurl I; Dünser M; Ramoni A; Gunsilius E; Eibl G; Mikuz G; Gastl G
Int J Cancer; 2002 Apr; 98(6):883-8. PubMed ID: 11948467
[TBL] [Abstract][Full Text] [Related]
24. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
25. CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis.
Albasri A; Aleskandarany M; Benhasouna A; Powe DG; Ellis IO; Ilyas M; Green AR
Breast Cancer Res Treat; 2011 Feb; 126(1):47-54. PubMed ID: 20390342
[TBL] [Abstract][Full Text] [Related]
26. WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition.
Prasad CP; Chaurasiya SK; Guilmain W; Andersson T
J Exp Clin Cancer Res; 2016 Sep; 35(1):144. PubMed ID: 27623766
[TBL] [Abstract][Full Text] [Related]
27. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
[TBL] [Abstract][Full Text] [Related]
28. Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.
Mohammad AM; Abdel HA; Abdel W; Ahmed AM; Wael T; Eiman G
Indian J Cancer; 2006; 43(4):163-8. PubMed ID: 17192687
[TBL] [Abstract][Full Text] [Related]
29. Identification of new cancer stem cell markers and signaling pathways in HER‑2‑positive breast cancer by transcriptome sequencing.
Feng L; Huang S; An G; Wang G; Gu S; Zhao X
Int J Oncol; 2019 Nov; 55(5):1003-1018. PubMed ID: 31545416
[TBL] [Abstract][Full Text] [Related]
30. Nm-23, c-erbB-2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters.
Nakopoulou LL; Tsitsimelis D; Lazaris AC; Tzonou A; Gakiopoulou H; Dicoglou CC; Davaris PS
Cancer Detect Prev; 1999; 23(4):297-308. PubMed ID: 10403901
[TBL] [Abstract][Full Text] [Related]
31. HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.
Desai K; Aiyappa R; Prabhu JS; Nair MG; Lawrence PV; Korlimarla A; Ce A; Alexander A; Kaluve RS; Manjunath S; Correa M; Srinath BS; Patil S; Kalamdani A; Prasad M; Sridhar TS
Tumour Biol; 2017 Mar; 39(3):1010428317695028. PubMed ID: 28349782
[TBL] [Abstract][Full Text] [Related]
32. Long non-coding RNA BANCR indicates poor prognosis for breast cancer and promotes cell proliferation and invasion.
Lou KX; Li ZH; Wang P; Liu Z; Chen Y; Wang XL; Cui HX
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1358-1365. PubMed ID: 29565494
[TBL] [Abstract][Full Text] [Related]
33. Integrin alpha-2 and beta-1 expression increases through multiple generations of the EDW01 patient-derived xenograft model of breast cancer-insight into their role in epithelial mesenchymal transition in vivo gained from an in vitro model system.
Wafai R; Williams ED; de Souza E; Simpson PT; McCart Reed AE; Kutasovic JR; Waltham M; Snell CE; Blick T; Thompson EW; Hugo HJ
Breast Cancer Res; 2020 Dec; 22(1):136. PubMed ID: 33276802
[TBL] [Abstract][Full Text] [Related]
34. TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway.
Zhang LY; Zhang YQ; Zeng YZ; Zhu JL; Chen H; Wei XL; Liu LJ
Breast Cancer Res Treat; 2020 Jul; 182(1):21-33. PubMed ID: 32415497
[TBL] [Abstract][Full Text] [Related]
35. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
36. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
38. Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.
Ziegler E; Hansen MT; Haase M; Emons G; Gründker C
Breast Cancer Res Treat; 2014 Nov; 148(2):269-77. PubMed ID: 25292421
[TBL] [Abstract][Full Text] [Related]
39. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
40. NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer.
Kong C; Wang C; Wang L; Ma M; Niu C; Sun X; Du J; Dong Z; Zhu S; Lu J; Huang B
PLoS One; 2011; 6(7):e22666. PubMed ID: 21829474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
